This study examines the ethical issues surrounding the use of Artificial Intelligence (AI) in healthcare, specifically nursing, under the European General Data Protection Regulation (GDPR). The analysis delves into how GDPR applies to healthcare AI projects, encompassing data collection and decision-making stages, to reveal the ethical implications at each step. A comprehensive review of the literature categorizes research investigations into three main categories: Ethical Considerations in AI; Practical Challenges and Solutions in AI Integration; and Legal and Policy Implications in AI. The analysis uncovers a significant research deficit in this field, with a particular focus on data owner rights and AI ethics within GDPR compliance. To address this gap, the study proposes new case studies that emphasize the importance of comprehending data owner rights and establishing ethical norms for AI use in medical applications, especially in nursing. This review makes a valuable contribution to the AI ethics debate and assists nursing and healthcare professionals in developing ethical AI practices. The insights provided help stakeholders navigate the intricate terrain of data protection, ethical considerations, and regulatory compliance in AI-driven healthcare. Lastly, the study introduces a case study of a real AI health-tech project named SENSOMATT, spotlighting GDPR and privacy issues.

Biofilms play a major role in delaying chronic wounds from healing. A wound infiltrated with biofilm, or “critically colonised” wound, may become clinically infected if the number of microbes exceeds a critical level. Chronic wound biofilms represent a significant treatment challenge by demonstrating recalcitrance towards antimicrobial agents. However, a “window of opportunity” may exist after wound debridement when biofilms are more susceptible to topical antiseptics. Here, we discuss the role of antiseptics in the management of chronic wounds and biofilm, focusing on povidone‐iodine (PVP‐I) in comparison with two commonly used antiseptics: polyhexanide (PHMB) and silver. This article is based on the literature reviewed during a focus group meeting on antiseptics in wound care and biofilm management, and on a PubMed search conducted in March 2020. Compared with PHMB and silver, PVP‐I has a broader spectrum of antimicrobial activity, potent antibiofilm efficacy, no acquired bacterial resistance or cross‐resistance, low cytotoxicity, good tolerability, and an ability to promote wound healing. PVP‐I represents a viable therapeutic option in wound care and biofilm management, with the potential to treat biofilm‐infiltrated, critically colonised wounds. We propose a practical algorithm to guide the management of chronic, non‐healing wounds due to critical colonisation or biofilm, using PVP‐I.